| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
The primary molecular target of Carsalam is not fully characterized, but as a non-steroidal anti-inflammatory agent, it is likely to inhibit cyclooxygenase (COX) enzymes, which are key mediators of the inflammatory response. COX enzymes catalyze the production of prostaglandins, which are lipid mediators that promote inflammation, pain, and fever. By inhibiting COX enzymes, Carsalam reduces the production of prostaglandins, thereby exerting its anti-inflammatory effects. The compound may also have other mechanisms of action, including modulation of immune cell function and inhibition of inflammatory cytokine production. Further research is needed to fully characterize its molecular targets.
|
|---|---|
| ln Vitro |
In vitro studies of Carsalam have demonstrated its anti-inflammatory activity. As an NSAID, it is likely to inhibit the production of prostaglandins by inhibiting COX enzymes. The compound may also modulate the production of inflammatory cytokines and chemokines. Its anti-inflammatory activity has been demonstrated in various in vitro models of inflammation. Carsalam is used as an antiseptic. The compound is used as a pharmaceutical building block and reference standard in pharmaceutical research. Its stability and purity are assessed by HPLC and other analytical methods.
|
| ln Vivo |
In vivo studies of Carsalam have demonstrated its anti-inflammatory and antiseptic properties. As a non-steroidal anti-inflammatory agent, it is used to reduce inflammation and pain. The compound has been used in various pharmaceutical formulations for the treatment of inflammatory conditions. In vivo protocols typically involve administration of Carsalam via oral or topical routes. Endpoints include assessment of inflammation, pain, and histopathological examination. However, detailed in vivo protocols and efficacy data are not extensively reported in the public domain.
|
| Enzyme Assay |
For anti-inflammatory assays, immune cells (e.g., macrophages) are cultured in appropriate medium and stimulated with LPS in the presence or absence of Carsalam (0.1-100 µM). After 4-24 hours, culture supernatants are collected, and cytokine levels (TNF-α, IL-1β, IL-6) are measured by ELISA. For COX inhibition assays, the activity of purified COX-1 or COX-2 enzymes is measured using a colorimetric or fluorometric assay. The enzyme is incubated with varying concentrations of Carsalam and a substrate (e.g., arachidonic acid). Product formation is measured, and IC50 values are calculated from dose-response curves. For antimicrobial assays, the compound is tested against bacterial strains to assess its antiseptic activity.
|
| Cell Assay |
For cellular studies, immune cells or other cell lines are cultured in appropriate medium (DMEM or RPMI-1640) with 10% FBS and antibiotics. Cells are seeded in 6-well or 96-well plates. Carsalam is dissolved in DMSO and diluted in culture medium to final concentrations (typically 0.1-100 µM). Cells are treated with the compound for 24-72 hours. Cell viability is assessed by MTT assay. Cytokine production is measured by ELISA. For mechanistic studies, cells are lysed and analyzed for COX expression and activity, as well as other signaling proteins, by Western blot.
|
| Animal Protocol |
For in vivo studies, animal models of inflammation (e.g., carrageenan-induced paw edema) are used. Carsalam is formulated in vehicle and administered orally or topically at doses determined from preliminary studies. Inflammation is assessed by measuring paw swelling or other appropriate endpoints. Histopathological examination of tissues is performed. For antiseptic studies, animal models of infection may be used. However, detailed in vivo protocols are not extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Carsalam are limited, as the compound is primarily used as a research reagent. As a small molecule with a molecular weight of 163.13, the compound is expected to have moderate oral bioavailability and tissue distribution. Its metabolism likely involves hepatic CYP450 enzymes, and it is cleared via biliary and renal excretion. However, no dedicated pharmacokinetic studies have been reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for Carsalam are limited, as the compound is a research reagent. No acute toxicity, organ-specific toxicity, or mutagenicity data have been reported. As with all chemical reagents, appropriate safety precautions should be taken when handling Carsalam, including the use of personal protective equipment and work in a well-ventilated area.
|
| Additional Infomation |
Carsalam is a benzoxazine.
Carsalam (CAS 2037-95-8), also known as Carbonylsalicylamide, is a non-steroidal anti-inflammatory agent (NSAID). It has a molecular formula of C₈H₅NO₃ and a molecular weight of 163.13. The compound is used as an antiseptic. It is a benzoxazine derivative and a small molecule drug. Carsalam is used as a pharmaceutical building block and reference standard. Its anti-inflammatory activity is likely mediated through COX inhibition. The compound is strictly for research use only. |
| Molecular Formula |
C8H5NO3
|
|---|---|
| Molecular Weight |
163.1302
|
| Exact Mass |
163.026
|
| CAS # |
2037-95-8
|
| PubChem CID |
16258
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Melting Point |
228-232ºC(lit.)
|
| Index of Refraction |
1.586
|
| LogP |
0.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
226
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(N([H])C(C2=C([H])C([H])=C([H])C([H])=C12)=O)=O
|
| InChi Key |
OAYRYNVEFFWSHK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H5NO3/c10-7-5-3-1-2-4-6(5)12-8(11)9-7/h1-4H,(H,9,10,11)
|
| Chemical Name |
1,3-benzoxazine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~120 mg/mL (~735.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (18.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (18.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.1301 mL | 30.6504 mL | 61.3008 mL | |
| 5 mM | 1.2260 mL | 6.1301 mL | 12.2602 mL | |
| 10 mM | 0.6130 mL | 3.0650 mL | 6.1301 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
